Pharmacovigilance for veterinary medicinal products
Veterinary medicinal products only receive marketing authorisation if the assessment of the data concerning their quality, safety and efficacy shows that the benefits linked to their use are greater than the risks incurred. The clinical trials conducted in the context of MA applications highlight a certain number of adverse effects which may occur when using medicinal products. However, these trials are conducted on a limited number of animals under standardised conditions of use. The large-scale use of a drug under real-life conditions once an MA is granted then makes it possible to precisely pinpoint the possible adverse effects of a product and to identify any potential risk factors (species, breed, age, pre-existing ailments, etc.).
Pharmacovigilance therefore aims to detect any emerging signs as quickly as possible, both unexpected adverse effects and known adverse effects with an unexpected frequency or severity. This post-MA monitoring sometimes results in adjusting risk management measures, which may include providing additional precautions for use on the package leaflet, or in certain cases withdrawal of the MA.
Here is a glimpse of the Agency's work on the topic.
Published on Read more
A surveillance scheme for the adverse effects of veterinary medicinal products has been in operation since 2002, and has provided an on-line declaration service since 2010. This drug monitoring plan makes it possible to detect adverse effects and to more effectively describe them in animals. Declaring adverse effects provides continuous monitoring of the risks and benefits of veterinary medicinal products after they have been placed on the market, and therefore promotes their safe use. Through your declarations, you help expand our knowledge of veterinary medicinal products, which in turn is of benefit to animals, their owners and all those involved in animal health.
The article has been added to your library